In Nov. 2022, the U.S. nonprofit Multidisciplinary Affiliation for Psychedelic scientific studies (MAPS) announced that it had concluded a second phase-3 demo on MDMA for a remedy for PTSD—a move broadly witnessed as https://marleyzaoz579304.plpwiki.com/user